Disease course of Neurofibromatosis Type 2; a 30-year follow-up study of 353 patients seen at a single institution
dc.contributor.author | Forde, C. | |
dc.contributor.author | King, A. T. | |
dc.contributor.author | Rutherford, S. A. | |
dc.contributor.author | Hammerbeck-Ward, C. | |
dc.contributor.author | Lloyd, S. K. | |
dc.contributor.author | Freeman, S. R. | |
dc.contributor.author | Pathmanaban, O. N. | |
dc.contributor.author | Stapleton, E. | |
dc.contributor.author | Thomas, O. M. | |
dc.contributor.author | Laitt, R. D. | |
dc.contributor.author | Stivaros, S. | |
dc.contributor.author | Kilday, J. P. | |
dc.contributor.author | Vassallo, G. | |
dc.contributor.author | McBain, Catherine A | |
dc.contributor.author | Kerrigan, S. | |
dc.contributor.author | Smith, M. J. | |
dc.contributor.author | McCabe, Martin | |
dc.contributor.author | Harkness, E. F. | |
dc.contributor.author | Evans, D. G. | |
dc.date.accessioned | 2021-01-25T01:13:45Z | |
dc.date.available | 2021-01-25T01:13:45Z | |
dc.date.issued | 2020 | en |
dc.identifier.citation | Forde C, King AT, Rutherford SA, Hammerbeck-Ward C, Lloyd SK, Freeman SR, et al. Disease course of Neurofibromatosis Type 2; a 30-year follow-up study of 353 patients seen at a single institution. Neuro Oncol. 2020. | en |
dc.identifier.pmid | 33336705 | en |
dc.identifier.doi | 10.1093/neuonc/noaa284 | en |
dc.identifier.uri | http://hdl.handle.net/10541/623720 | |
dc.description.abstract | Background: Limited data exists on the disease course of Neurofibromatosis Type 2 (NF2) to guide clinical trial design. Methods: A prospective database of patients meeting NF2 diagnostic criteria, reviewed between 1990-2020, was evaluated. Follow-up to first vestibular schwannoma (VS) intervention and death was assessed by univariate analysis and stratified by age at onset, era referred and inheritance type. Interventions for NF2-related tumours were assessed. Cox regression was performed to determine the relationship between individual factors from time of diagnosis to NF2-related death. Results: Three-hundred-and-fifty-three patients were evaluated. During 4643.1 follow-up years from diagnosis to censoring 60 patients (17.0%) died. The annual mean number of patients undergoing VS surgery or radiotherapy declined, from 4.66 and 1.65 respectively per 100 NF2 patients in 1990-1999 to 2.11 and 1.01 in 2010-2020, as the number receiving bevacizumab increased (2.51 per 100 NF2 patients in 2010-2020). Five patients stopped bevacizumab to remove growing meningioma or spinal schwannoma. 153/353 (43.3%) had at least one neurosurgical intervention/radiation treatment within 5 years of diagnosis. Patients asymptomatic at diagnosis had longer time to intervention and better survival compared to those presenting with symptoms. Those symptomatically presenting <16 and >40 years had poorer overall survival than those presenting at 26-39 years (P=0.03 and P=0.02 respectively) but those presenting between 16-39 had shorter time to VS intervention. Individuals with de novo constitutional variants had worse survival than those with de novo mosaic or inherited disease (P=0.004). Conclusion: Understanding disease course improves prognostication, allowing for better informed decisions about care. | en |
dc.language.iso | en | en |
dc.relation.url | https://dx.doi.org/10.1093/neuonc/noaa284 | en |
dc.title | Disease course of Neurofibromatosis Type 2; a 30-year follow-up study of 353 patients seen at a single institution | en |
dc.type | Article | en |
dc.contributor.department | Manchester Centre for Genomic Medicine, Manchester Academic Health Science Centre, Division of Evolution and Genomic Medicine, University of Manchester, St Mary's Hospital, Manchester Universities NHS Foundation Trust, Manchester, | en |
dc.identifier.journal | Neuro Oncology | en |
dc.description.note | en] |